Study of leftover tumor after chemo and trastuzumab
Part of Cancer clinical trials.
This study looks at leftover breast cancer cells (after chemo and targeted therapy) to find out why some cells resist treatment. It may help doctors better understand how to treat HER2-positive breast cancer in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing to give permission to be in the study.
- You received chemotherapy (anthracyclines then taxanes) plus trastuzumab before surgery.
- After surgery, you had cancer cells still present in the breast or lymph nodes.
- Your stored tumor sample is good quality for special testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for tiny traces of cancer after treatment by testing blood for “ctDNA,” which is leftover cancer DNA. It includes people with HER2-positive early breast cancer who are getting chemotherapy before surgery to see if this blood test can detect signs of remaining disease.
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
This trial looks at whether Herceptin (trastuzumab) can be used as after-treatment with less chemotherapy for certain early breast cancers. It may help reduce how much chemotherapy you need, while still lowering the chance the cancer comes back.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.